Lavaca Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Lavaca Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-12	Closed	-$2K	–	389
2019 Q1	$2K	Hold	12	–	–	﹤0.01%	365
2018 Q4	$1K	Buy	+12	New	+$1.42K	﹤0.01%	367

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Lavaca Capital's ALXN Position: Q2 2019 in Review

Lavaca Capital sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 12 shares — an estimated $2K sold.

Lavaca Capital first reported a position in ALXN in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

Lavaca Capital reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Lavaca Capital sold 12 Alexion Pharmaceuticals shares in Q2 2019, an estimated $2K.
Lavaca Capital first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Lavaca Capital's Alexion Pharmaceuticals position peaked at $2K in Q1 2019.
636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on Lavaca Capital's 13F filing for Q2 2019, filed 29 Jul 2019.